Buscar
Mostrando ítems 11-20 de 80
Prognostic significance of BCR-ABL rearrangement in chronic myeloid leukemia
(Assoc Bras Divulg CientificaSao PauloBrasil, 1996)
Early detection and quantification of mutations in the tyrosine kinase domain of chimerical BCR-ABL1 gene combining high-resolution melting analysis and mutant-allele specific quantitative polymerase chain reaction
(Taylor & Francis, 2013-03)
BCR–ABL1 point mutations are the most common cause of resistance in patients with chronic myeloid leukemia (CML) who fail or lose response to tyrosine kinase inhibitors. We have developed a rapid method to screen BCR–ABL1 ...
Molecular and chromosomal mutations among children with B-lineage lymphoblastic leukemia in Brazil's Federal District
(Funpec-editoraRibeirao PretoBrasil, 2009)
Establishment and Validation of Analytical Reference Panels for the Standardization of Quantitative BCR-ABL1 Measurements on the International Scale
(Amer Assoc Clinical ChemistryWashingtonEUA, 2013)
Standardization of molecular monitoring for chronic myeloid leukemia in Latin America using locally produced secondary cellular calibrators
(Nature Publishing Group, 2016-12)
Residual disease in chronic myeloid leukemia (CML) patients undergoing therapy with tyrosine kinase inhibitors (TKIs) is measured by assessing the quantity of transcripts of the BCR-ABL1 fusion gene in peripheral white ...
Análisis de la Expresión de los Genes Bcr-Abl y HoxA9 en Leucemia Mieloide Crónica
(2011-08-23)
La leucemia mieloide crónica (LMC) resulta de la transformación neoplásica de las células madre hematopoyéticas. Su sello distintivo es una anomalía genética: la traslocación t(9;22)(q34;q11). Esta genera el gen de fusión ...
Leukemia (Ph+): diagnosis and treatmentLeucemia Mieloide Crónica (Ph+): diagnóstico y tratamiento
(Universidad de Costa Rica, 2013)
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
(Amer Soc HematologyWashingtonEUA, 2014)